提高淋巴瘤自体造血细胞移植疗效的策略。
Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.
机构信息
Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weill Cornell Medical College, New York, NY, USA.
出版信息
Bone Marrow Transplant. 2019 Jul;54(7):943-960. doi: 10.1038/s41409-018-0378-z. Epub 2018 Nov 2.
Abstract
High-dose chemotherapy and autologous hematopoietic cell transplantation (HDT-AHCT) remains an effective therapy in lymphoma. Over the past several decades, HDT with BEAM (carmustine, etoposide, cytarabine, and melphalan) and CBV (cyclophosphamide, carmustine, and etoposide) have been the most frequently used preparatory regimens for AHCT in Hodgkin (HL) and non-Hodgkin lymphoma (NHL). This article reviews alternative combination conditioning regimens, as well as novel transplant strategies that have been developed, to reduce transplant-related toxicity while maintaining or improving efficacy. These data demonstrate that incorporation of maintenance therapy posttransplant might be the best way to improve outcomes.
摘要
大剂量化疗和自体造血细胞移植（HDT-AHCT）仍然是淋巴瘤的有效治疗方法。在过去的几十年中，BEAM（卡莫司汀、依托泊苷、阿糖胞苷和马法兰）和 CBV（环磷酰胺、卡莫司汀和依托泊苷）联合 HDT 已成为霍奇金淋巴瘤（HL）和非霍奇金淋巴瘤（NHL）中 AHCT 最常使用的预处理方案。本文综述了替代联合调理方案以及新的移植策略，这些策略的发展旨在降低移植相关毒性，同时保持或提高疗效。这些数据表明，移植后进行维持治疗可能是改善预后的最佳方法。
相似文献
1
Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.
Bone Marrow Transplant. 2019 Jul;54(7):943-960. doi: 10.1038/s41409-018-0378-z. Epub 2018 Nov 2.
2
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
Biol Blood Marrow Transplant. 2015 Jun;21(6):1046-1053. doi: 10.1016/j.bbmt.2015.02.005. Epub 2015 Feb 14.
3
Early Toxicity and Efficacy of Four Different Conditioning Regimens for Autologous Hematopoietic Cell Transplantation in Patients With Lymphoma: Impact of Drug Shortages in a Resource-Constrained Country.
Transplant Cell Ther. 2024 Oct;30(10):1003.e1-1003.e9. doi: 10.1016/j.jtct.2024.07.025. Epub 2024 Aug 2.
4
Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2016 Dec;22(12):2155-2158. doi: 10.1016/j.bbmt.2016.08.026. Epub 2016 Aug 26.
5
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Biol Blood Marrow Transplant. 2016 Jul;22(7):1197-1205. doi: 10.1016/j.bbmt.2016.03.018. Epub 2016 Mar 31.
6
Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Cytotherapy. 2024 May;26(5):456-465. doi: 10.1016/j.jcyt.2024.01.012. Epub 2024 Feb 19.
7
Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):417-23. doi: 10.1016/j.clml.2013.03.009. Epub 2013 Jun 15.
8
Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):272-279. doi: 10.1016/j.clml.2018.02.008. Epub 2018 Feb 15.
9
Gemcitabine-based conditioning compared to BEAM/BEAC conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: No difference in outcomes.
Cancer Med. 2024 Jan;13(2):e6965. doi: 10.1002/cam4.6965.
10
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29.
引用本文的文献
1
Abnormally high expression of CHI3L1 in peripheral blood mononuclear cells and serum and their potential diagnosis and prediction from lymphoma patients.
Front Immunol. 2025 Apr 7;16:1557802. doi: 10.3389/fimmu.2025.1557802. eCollection 2025.
2
Women's Sexual Dysfunctions Following Stem Cell Transplant and the Impact on Couple Relationship.
Life (Basel). 2023 Dec 25;14(1):35. doi: 10.3390/life14010035.
3
A pilot study of cord blood-derived natural killer cells as maintenance therapy after autologous hematopoietic stem cell transplantation.
Ann Hematol. 2023 Nov;102(11):3229-3237. doi: 10.1007/s00277-023-05471-4. Epub 2023 Sep 29.
4
[A comparison of C+SCAV and SEAM conditioning regimens in efficacy and safety in autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma patients].
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):668-673. doi: 10.3760/cma.j.issn.0253-2727.2022.08.009.
5
Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.
Clin Pharmacokinet. 2022 Apr;61(4):553-563. doi: 10.1007/s40262-021-01093-z. Epub 2021 Dec 2.
6
Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation.
J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):962-972. doi: 10.1002/jcsm.12570. Epub 2020 Mar 25.
本文引用的文献
1
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Am J Hematol. 2020 Jul;95(7):775-783. doi: 10.1002/ajh.25818. Epub 2020 Apr 22.
2
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3.
3
High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party.
Bone Marrow Transplant. 2018 Dec;53(12):1553-1559. doi: 10.1038/s41409-018-0196-3. Epub 2018 Jun 8.
4
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Biol Blood Marrow Transplant. 2018 Sep;24(9):1814-1822. doi: 10.1016/j.bbmt.2018.05.018. Epub 2018 May 29.
5
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
Br J Haematol. 2018 May;181(3):341-349. doi: 10.1111/bjh.15184. Epub 2018 Apr 2.
6
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Biol Blood Marrow Transplant. 2018 Aug;24(8):1602-1609. doi: 10.1016/j.bbmt.2018.02.020. Epub 2018 Mar 2.
7
Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):272-279. doi: 10.1016/j.clml.2018.02.008. Epub 2018 Feb 15.
8
Updated Results of Rituximab Pre- and Post-BEAM with or without Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.
Clin Cancer Res. 2018 May 15;24(10):2304-2311. doi: 10.1158/1078-0432.CCR-17-3561. Epub 2018 Feb 23.
9
Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.
Am J Hematol. 2018 Jun;93(6):729-735. doi: 10.1002/ajh.25077. Epub 2018 Mar 14.
10
Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).
Biol Blood Marrow Transplant. 2018 Apr;24(4):700-707. doi: 10.1016/j.bbmt.2017.12.798. Epub 2017 Dec 28.
Zotero 插件